乙型肝炎病毒基因型与阿德福韦酯治疗效应的关系  

Relationship Between HepatitisB Virus Genotypes and Effect of Adeforvir Dipivoxil

作　　者：李世波[1] 丁贤君[1] 李绍佐[1] 

机构地区：[1]浙江省舟山市人民医院感染科,舟山316000

出　　处：《浙江中西医结合杂志》2007年第9期532-534,共3页Zhejiang Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的:探讨乙型肝炎病毒基因型与阿德福韦酯治疗效应的关系。方法:采用聚合酶链式反应(PCR)结合TaqmanMGB探针技术,对血清中HBV基因型进行分型检测,观察63例不同基因型慢性乙型病毒性肝炎患者经阿德福韦酯(商品名:贺维力)治疗后ALT水平、HBVDNA定量、HBeAg血清转换情况。结果:63例HBV患者中B基因型17例(27.0%),C基因型46例(73.0%)。阿德福韦酯治疗3个月与治疗12个月时B基因型与C基因型两组间ALT、HBVDNA水平差异无显著性意义(P>0.05)。而治疗6、9个月后,两组ALT、HBVDNA水平差异有显著性意义(P<0.01),阿德福韦酯对B基因型疗效优于C型;治疗12个月,B、C基因型HBeAg血清转换率差异有显著性意义(P<0.05)。结论:短期观察HBV基因型与阿德福韦酯的治疗效应存在一定的相关性,HBV基因B型患者HBeAg血清转换率高于C型患者。Objective：To investigate the relationship between hepatitisB virus genotype and effect of adeforvir dipivoxil （ADV）. Methods：63 eases of chronic hepatitisB （CHB） with different genotypes were detected by PCR combined with Taqman MGB probe teehnique. The ALT level, quantum HBVDNA and HBeAg plarna exehange were observed after therapy with ADV. Results：Among 63 eases of CHB, there are 17 eases with genotype B （27%） and 46 cases with genotype C （73%）. The level of ALT and HBVDNA in eases with genotype B and C after 3 months＇therapy and 12 months＇therapy had no signifieant differenee （ P 〉 0.05 ）. While the level of ALT and HBVDNA in eases with genotype B and C after 6 months＇therapy and 9 months＇therapy had signifieant differenee（ P 〈0.01 ）. The effeet of ADV on cases with genotype B was better than that on genotype C. The exehange ratio of HBeAg in eases with genotype B and C after 12 months＇therapy had obvious difference （P 〈0.05）. Conclusion：The curative effect of ADV is related with the genotype of CHB through observation for short time. The exehange ratio of HBeAg in eases with genotype B is higher than that in genotype C.

关 键 词：乙型肝炎病毒 基因型 阿德福韦酯 治疗效应 

分 类 号：R512.62[医药卫生—内科学]